3Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol, 2004, 16 (3): 180- 185.
4Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disea.Clin Exp Rheumatol, 2007, 25( 1 ): 23-28.
5Lehembre S, Macario-Barrel A, Musette P, et al. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus.Ann Dermatol Venereol, 2006, 133 (1): 53-55.
6Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol, 2006, 18 (5): 503-506.
7Petschner F, Walker UA, Schmitt-Graff A, et al. “Catastrophic systemic lupus erythematosus” with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr, 2001, 126(37): 998-1001.
8Stierle HE. New strategies in diagnosis and therapy of vasculitides. Med Klin (Munich), 2006, 101: 143-146.
9Marzano AV, Fanoni D, Venegoni L, et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology, 2007, 214(4): 310-318.
10Leon A, Nguyen A, Letsinger J, et al. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother, 2007, 8(5): 617-632.
